On January 21, 2026, Bayer Aktiengesellschaft (BAYRY) was named to the Zacks Rank #1 (Strong Buy) value stocks list for January 21st, joining fellow names BNPQY and DLAKY. The designation reflects Zacks’s proprietary quantitative model, which identified BAYRY’s five-star Value Score based on its low forward price-to-earnings ratio relative to industry peers, above-average earnings yield and discounted two-year trailing cash flow multiples. This recognition highlights investor interest in BAYRY’s defensive pharmaceutical and crop science divisions as generic competition pressures ease.

Bayer’s pharmaceuticals division is a named partner in Arvinas’s multi-billion-dollar collaborations to advance targeted protein degradation therapies, according to Arvinas disclosures. These agreements, signed in late 2025, include upfront payments totaling $250 million and potential milestones exceeding $2.5 billion per collaboration. Bayer gains exclusive rights to develop and commercialize select PROTAC candidates in oncology and immunology, while Arvinas secures research funding and tiered royalties. The partnerships position BAYRY to capitalize on a market forecasted to exceed $10 billion by 2030, leveraging its global regulatory expertise and commercial infrastructure.